CMN Weekly (9 May 2025) - Your Weekly CRISPR...
CMN Weekly
May. 9, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
EMERZENE
Company Type: Therapeutics
Main focus: CRISPR-Cas, pain relief therapeutics
Company stage: Pre-clinical
Diseases: Pain
Genome-editing tool: CRISPR-Cas
Funding stage: Seed Funding
Location: California and Australia
Website: https://emerzene.com/
Pipeline: https://emerzene.com/pipeline/
Partners: Merck, NiST
Emerzene is a pre-clinical-stage company that employs CRISPR-Cas gene editing and cutting-edge farming techniques to engineer new strains of poppy. The final goal is to develop a new class of opioid-derived painkillers that do not induce addiction over a long period of time.
